M&A Deal Summary |
|
|---|---|
| Date | 2004-12-21 |
| Target | ILEX Oncology |
| Sector | Life Science |
| Buyer(s) | Genzyme |
| Sellers(s) |
Nexus Life Science Partners
Boston Millennia Partners Alta Partners Perseus |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.0B USD |
SEARCH BY
Try For Free 7-Day Free Trial
Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 12 |
| Sector (Life Science) | 5 of 9 |
| Type (Add-on Acquisition) | 6 of 10 |
| State (Texas) | 1 of 1 |
| Country (United States) | 7 of 9 |
| Year (2004) | 1 of 1 |
| Size (of disclosed) | 1 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-09-10 |
SangStat Medical
Fremont, California, United States SangStat Medical Corp. is a biotechnology company focused on immunology and working to discover, develop and market high value therapeutic products in the autoimmune, hematology/oncology and immunosuppression areas. |
Buy | $600M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-02-28 |
Verigen AG
Leverkusen, Germany Verigen AG, a private company based in Germany with a proprietary cell therapy product for cartilage repair currently sold in Europe and Australia. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 2001 |
| Size | Small |
| Type | Sector Focused |
Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 22 |
| Sector (Life Science) | 3 of 18 |
| Type (Add-on Acquisition) | 1 of 10 |
| State (Texas) | 1 of 1 |
| Country (United States) | 3 of 19 |
| Year (2004) | 2 of 2 |
| Size (of disclosed) | 3 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-02-27 |
Pharmacopeia
Cranbury, New Jersey, United States Pharmacopeia, Inc. is a Drug Discovery identifying and developing small molecule drug candidates, with a primary focus on immunological diseases. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-07-20 |
Guilford Pharmaceuticals
Baltimore, Maryland, United States Guilford Pharmaceuticals discovered, developed and marketed pharmaceutical products, targeting the hospital and neurological markets. The company was acquired by MGI Pharma (Nasdaq: MOGN), an oncology and acute care focused biopharmaceutical company |
Sell | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1984 |
| PE ASSETS | 700M USD |
| Size | Middle-Market |
| Type | Sector Agnostic |
Boston Millenia Partners is a growth capital investment firm focused rapidly growing business services and healthcare companies. The Firm generally looks to invest $3 to $10 million in companies at or near profitability with $3 to $30 million in sales. Boston Millenia's geographic preference is for opportunities in the Eastern half of the US. Boston Millenia Partners was formed in 1984 and has a single office in Boston.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 15 |
| Sector (Life Science) | 1 of 4 |
| Type (Add-on Acquisition) | 1 of 10 |
| State (Texas) | 1 of 1 |
| Country (United States) | 1 of 15 |
| Year (2004) | 1 of 1 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-10-29 |
Arthrosurface
Franklin, Massachusetts, United States Arthrosurface is a provider of joint surface and preservation solutions for active patients. Arthrosurface was founded in 2001 and is based in Franklin, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-02-22 |
V-SPAN
King of Prussia, Pennsylvania, United States V-SPAN, Inc. is a provider of premium conferencing services to businesses. V-SPAN's services include video conference bridging (integrating two or more video conference participants into a single video output), automated audio conferencing, document web conferencing, Internet streaming and storage, and other related premium conferencing services. V-SPAN was founded in 1995 and is based in King of Prussia, Pennsylvania. |
Sell | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 2.6B USD |
| Size | Large |
| Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 19 of 84 |
| Sector (Life Science) | 10 of 64 |
| Type (Add-on Acquisition) | 12 of 45 |
| State (Texas) | 1 of 2 |
| Country (United States) | 18 of 74 |
| Year (2004) | 6 of 6 |
| Size (of disclosed) | 3 of 23 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-12-10 |
Definity Health
St. Louis Park, Minnesota, United States Definity Health, founded in 1999, is a provider in consumer-driven health benefit programs. |
Sell | $300M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-01-01 |
Silence Therapeutics
London, United Kingdom Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Silence Therapeutics proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, Silence Therapeutics has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence Therapeutics was incorporated in 1994 and is based in London, United Kingdom. |
Sell | - |
| Category | Merchant Bank |
|---|---|
| Founded | 1995 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Agnostic |
Perseus is a private equity firm focused on middle-market buyouts, recapitalizations, and growth equity investments. Perseus looks businesses operating with proven management, strong brands, and 'powerful intellectual property'. Sectors of interest include biotechnology, medical devices, branded consumer products, business services, information technology, communications, and energy/environmental service companies. Perseus was formed in 1995 and maintains offices in Washington DC, New York City, and Munich.
| DEAL STATS | # |
|---|---|
| Overall | 13 of 31 |
| Sector (Life Science) | 5 of 5 |
| Type (Add-on Acquisition) | 11 of 22 |
| State (Texas) | 2 of 3 |
| Country (United States) | 12 of 27 |
| Year (2004) | 1 of 1 |
| Size (of disclosed) | 1 of 8 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-07-21 |
Cardiac Science
Waukesha, Wisconsin, United States Cardiac Science Corp. is a developer, manufacturer, and marketer of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. Cardiac Science Corp. was founded in 1913 and is based in Waukesha, Wisconsin. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-04-07 |
MTN Satellite Communications
Miramar, Florida, United States MTN Satellite Communications, Inc. is a provider of communications and content services for remote locations around the world. |
Buy | $110M |
